Inhalable GSH-Triggered Nanoparticles to Treat Commensal Bacterial Infection in In Situ Lung Tumors

ACS Nano. 2023 Mar 28;17(6):5740-5756. doi: 10.1021/acsnano.2c12165. Epub 2023 Mar 8.

Abstract

Bacterial infection has been considered one of the primary reasons for low survival rate of lung cancer patients. Herein, we demonstrated that a kind of mesoporous silica nanoparticles loaded with anticancer drug doxorubicin (DOX) and antimicrobial peptide HHC36 (AMP) (MSN@DOX-AMP) can kill both commensal bacteria and tumor cells under GSH-triggering, modulating the immunosuppressive tumor microenvironment, significantly treating commensal bacterial infection, and eliminating in situ lung tumors in a commensal model. Meanwhile, MSN@DOX-AMP encapsulated DOX and AMP highly efficiently via a combined strategy of physical adsorption and click chemistry and exhibited excellent hemocompatibility and biocompatibility. Importantly, MSN@DOX-AMP could be inhaled and accumulate in lung by a needle-free nebulization, achieving a better therapeutic effect. This system is expected to serve as a straightforward platform to treat commensal bacterial infections in tumors and promote the translation of such inhaled GSH-triggered MSN@DOX-AMP to clinical treatments of lung cancer.

Keywords: antimicrobial peptide; click chemistry; commensal bacteria; lung cancer; nebulized inhalation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Infections* / drug therapy
  • Doxorubicin / pharmacology
  • Doxorubicin / therapeutic use
  • Drug Carriers
  • Drug Delivery Systems
  • Humans
  • Lung
  • Lung Neoplasms* / drug therapy
  • Nanoparticles* / therapeutic use
  • Porosity
  • Silicon Dioxide
  • Tumor Microenvironment

Substances

  • Drug Carriers
  • Doxorubicin
  • Silicon Dioxide